In particular, low baseline levels of HGF and GAS6, cognate ligands for MET and AXL, were prognostic for improved PFS or OS with cabozantinib treatment, supporting further studies of these biomarkers in patients with advanced RCC, where several TKI-immuno-oncology combinations, including cabozantinib and nivolumab, have demonstrated clinical benefit. The gene discussed is AXL; the disease is renal cell carcinoma.